Preview

Title

Advanced search

Pneumococcal Immunization in Young Children with Chronic Heart Failure

https://doi.org/10.31550/1727-2378-2023-22-3-15-21

Abstract

Aim: To determine the coverage, efficacy and tolerability of pneumococcal vaccination in young children with cardiovascular disease associated with chronic heart failure.

Design: Retro- and prospective randomized comparative study.

Materials and methods. The study included 250 patients at the age of 2 months to 5 years with confirmed chronic cardiac failure caused by cardiomyopathy or congenital heart disorder. Within the scope of a specialised laboratory and instrumental examination, all children underwent an assessment of specific immunoglobulin (Ig) levels to the most common pneumococcal serotypes (1-5, 6B, 7F, 8, 9N, 9V, 10A, 11A,12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) using VaccZyme Anti-PCP IgG test system. During consultations and vaccination schedule development, pneumococcal vaccination coverage and the reasons for long-term medical exemptions or refusals were analysed. Provided the primary disease was stable, there were no contraindications and a parent gave their consent, patients were vaccinated with 13-valent pneumococcal conjugate vaccine (PCV13).

Results. When questioning the parents of patients, it was revealed that before admission to the department, only 97 (38.8%) patients received at least 1 dose of pneumococcal vaccine, while the remaining 153 (61.2%) were not vaccinated. During hospitalization, 65 (42.5%) of 153 unvaccinated patients under 5 years of age who had not received a single pneumococcal vaccine received the first dose (V1) of PCV13; of 97 children vaccinated, 20 (20.6%) received a second dose, 18 (18.6%) — pneumococcal booster. There was a significant difference in the levels of antibodies to Streptococcus pneumoniae between the group of patients who received a full course 16 | | Vol. 22, No. 3 (2023) of immunization according to age and the group of unvaccinated children: 108.1 ± 58.4 vs. 12.14 ± 7.8 mg/l (p < 0.05). In children with an incomplete course of vaccination, the levels of specific IgG to pneumococcal serotypes were lower. In groups of children who received only one dose of the vaccine in the first or second year of life, they amounted to 42.2 ± 11.7 and 40.2 ± 16.2 mg/l, respectively. Children who received at least two doses of vaccine without revaccination (starting before 12 months) had a relatively higher level of 68.2 ± 6.3 mg/L. But, despite a clear trend, there was no significant difference between these groups in our study. In the post-vaccination period, no serious complications were recorded in the examined children.

Conclusion. Vaccination against pneumococcal infection in children with chronic heart failure is effective, safe and should be carried out as close as possible to the schedule of the national vaccination calendar, with a limited set of contraindications.

About the Authors

M. K. Kurdup
National Medical Research Center for Children’s Health
Russian Federation

2 Lomonosov Ave., build. 1, Moscow, 119296



A. P. Fisenko
National Medical Research Center for Children’s Health
Russian Federation

2 Lomonosov Ave., build. 1, Moscow, 119296



I. V. Davydova
National Medical Research Center for Children’s Health
Russian Federation

2 Lomonosov Ave., build. 1, Moscow, 119296



A. A. Zhuzhula
National Medical Research Center for Children’s Health
Russian Federation

2 Lomonosov Ave., build. 1, Moscow, 119296



N. M. Alyabieva
National Medical Research Center for Children’s Health
Russian Federation

2 Lomonosov Ave., build. 1, Moscow, 119296



E. N. Basargina
National Medical Research Center for Children’s Health
Russian Federation

2 Lomonosov Ave., build. 1, Moscow, 119296



References

1. Briko N.I., Korshunov V.A., Lomonosov K.S. Pneumococcal infection in Russia: state of the issue. Annals of the Russian Academy of Medical Sciences. 2021;76(1):28–42. (in Russian) DOI: 10.15690/vramn1404

2. Walter E.B., Smith M.J. Prevention of pneumococcal infections in childhood: two decades of progress. Curr. Opin. Pediatr. 2022;34(2):140–6. DOI: 10.1097/MOP.0000000000001112

3. Briko N.I., Namazova-Baranova L.S., Kostinov M.P., Simonova E.G. et al. Pneumococcal disease aetiology. Causative agent antibiotic resistance. In: Briko N.I., ed. Epidemiology, clinical signs and prevention of pneumococcal infection. M.: Remedium Privolzhiye; 2017: 20–1. (in Russian)

4. Subramanian K., Henriques-Normark B., Normark S. Emerging concepts in the pathogenesis of the Streptococcus pneumoniae: from nasopharyngeal colonizer to intracellular pathogen. Cell Microbiol. 2019;21(11):e13077. DOI: 10.1111/cmi.13077

5. Arutyunov A.G., Rylova A.K., Arutyunov G.P. Pneumonia in hospitalized patients with circulatory decompensation (Registry of Pavlov Hospital). Russian Heart Failure Journal. 2014;15(3):146–59. (in Russian)

6. Kozlov R.S., Andreeva I.V., Stetsiouk O.U., Muraviov A.A. Pneumococcal vaccination in adult patients with comorbidities: a review of the clinical practice guidelines. Clinical Microbiology and Antimicrobial Chemotherapy. 2020;22(4):254–65. (in Russian). DOI: 10.36488/cmac.2020.4.254-265

7. Alekseeva E.I., Van’kova D.D., Soloshenko M.A., Dvoryakovskaya T.M. et al. Pneumococcal vaccine in patients with systemic juvenile idiopathic arthritis receiving biologic therapy: international practice review. Current Pediatrics. 2019;18(2):101– 8. (in Russian). DOI: 10.15690/vsp.v18i2.2012

8. Mayanskiy N.A., Grechukha T.A., Zubkova I.V., Korolkova E.L. et al. Anti-pneumococcal antibody level and its dynamics after immunization with polysaccharide pneumococcal vaccine in children with nephrotic syndrome. Diagnostic Issues in Pediatrics. 2011;3(3):42–6. (in Russian)

9. Kurdup M.K., Galitskaya M.G., Davydova I.V., Fisenko A.P. et al. Pneumococcal vaccination of children with chronic heart disease. Doctor.Ru. 2022;21(3):17–21. (in Russian). DOI: 10.31550/1727-2378-2022-21-3-17-21

10. Novopoltseva E.G., Tarasova A.A., Pogodina E.V., Krylova A.N. et al. Analysis of vaccination of children with congenital heart disorders in Nizhny Novgorod region. Russian Journal of Cardiology. 2021;26(S5):57–8. (in Russian)

11. Il'ina S.V., Lyisanov Yu.I. Vaccination of premature infants and children with congenital heart disease in Irkutsk using conjugated pneumococcal vaccines. Pediatric Pharmacology. 2013;10(3):12–16. (in Russian). DOI: 10.15690/pf.v10i3.692

12. Solórzano-Santos F., Espinoza-García L., Aguilar-Martínez G., Beirana-Palencia L. et al. Pneumococcal conjugate vaccine and pneumonia prevention in children with congenital heart disease. Rev. Invest. Clin. 2017;69(5):270–3. DOI: 10.24875/ric.17002241

13. Briko N.I., Lobzin Yu.V., Baranov A.A., Namazova-Baranova L.S. et al. Assessment of vaccination program effectiveness: basic approaches and issues. Pediatric Pharmacology. 2014;11(4):8–15. (in Russian). DOI: 10.15690/pf.v11i4.1057

14. Kostinov M.P. Vaccination of patients with cardiovascular diseases. In: Kostinov M.P., ed. Adult vaccination: from strategy to tactics. M.: MDV Group; 2020: 93–7. (in Russian)

15. Tatochenko V.K., Ozeretskovskiy N.A. Vaccination in risk groups. In: Tatochenko V.K., ed. Immunological prophylaxis-2020. M.: Pediatr; 2020: 184–5. (in Russian)

16. Lazareva M.A., Kulichenko T.V., Alyab'eva N.M., Ponomarenko O.A. et al. Nasopharyngeal carriage of Streptococcus pneumoniae in orphans, preschool children and unorganized children under 5 years. Current Pediatrics. 2015;14(2):246–55. (in Russian). DOI: 10.15690/vsp.v14i2.1293

17. Beisegulova G.N., Ramazanova B.A., Mustafina K.K., Koloskova E.A. Actual clinical and epidemiological aspects of pneumococcal infections (literature review). Vestnik KazNMU. 2020;2:87–92. (in Russian)


Review

For citations:


Kurdup M.K., Fisenko A.P., Davydova I.V., Zhuzhula A.A., Alyabieva N.M., Basargina E.N. Pneumococcal Immunization in Young Children with Chronic Heart Failure. PEDIATRICS. 2023;22(3):15-21. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-3-15-21

Views: 16


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1727-2378 (Print)
ISSN 2713-2994 (Online)